KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Work In Process (2017 - 2020)

Amneal Pharmaceuticals (AMRX) has 4 years of Work In Process data on record, last reported at $53.1 million in Q1 2020.

  • For Q1 2020, Work In Process changed N/A year-over-year to $53.1 million; the TTM value through Mar 2020 reached $53.1 million, changed N/A, while the annual FY2019 figure was $58.2 million, 7.45% up from the prior year.
  • Work In Process reached $53.1 million in Q1 2020 per AMRX's latest filing, down from $58.2 million in the prior quarter.
  • Across five years, Work In Process topped out at $59.2 million in Q2 2018 and bottomed at $38.1 million in Q4 2017.
  • Average Work In Process over 4 years is $50.4 million, with a median of $52.1 million recorded in 2018.
  • Peak YoY movement for Work In Process: soared 41.96% in 2018, then plummeted 35.13% in 2019.
  • A 4-year view of Work In Process shows it stood at $38.1 million in 2017, then skyrocketed by 41.96% to $54.2 million in 2018, then increased by 7.45% to $58.2 million in 2019, then decreased by 8.79% to $53.1 million in 2020.
  • Per Business Quant database, its latest 3 readings for Work In Process were $53.1 million in Q1 2020, $58.2 million in Q4 2019, and $50.8 million in Q3 2019.